


Hikal Limited

Positive start to FY19 with Strong Performance in Q1

- ✓ Sales of Rs. 326 Crore; Growth of 22%
- ✓ EBITDA of Rs. 61 Crore; Growth of 22%
- ✓ PBT of Rs. 23 Crore; Growth of 28%

Mumbai, August 8th, 2018: Hikal Ltd, a preferred long-term partner for leading global life sciences companies, announced its financial results for the quarter ended 30th June, 2018.

Highlights for Quarter Ended 30th June, 2018



Segmental Performance for the quarter ended 30th June, 2018

- **Crop Protection sales up 41% to Rs. 149 crore** as compared to Rs. 106 crore in the corresponding period of the previous year
- **Pharmaceutical sales up 10% to Rs. 177 crore** as compared to Rs. 161 crore in the corresponding period of the previous year

Commenting on the results, Jai Hiremath, Chairman & Managing Director, Hikal Ltd. said,

“We are off to a good start in Q1. Our Crop Protection business recorded a 41% growth in sales on higher offtake of our existing and new products. We undertook a plant expansion at our pharmaceutical site at Bangalore, which required us to shut down one of the plants for 3 weeks, resulting in lower production during April. In spite of this, the pharmaceutical business grew by 10%.

I am pleased to inform you that ICRA (affiliate of Moody's) has upgraded our credit rating from A-(stable) to A (stable).

We are planning significant investments in the coming two years to meet the growing demand in both our divisions for our existing products, and new products which have been developed at our R&T centre in Pune.

I am hopeful of continuing the growth momentum in the next 3 quarters.”

About Hikal Limited

Hikal is a reliable long-term partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates, manufactured using stringent global quality standards, for its global customers. Hikal’s advanced manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja and Mahad (Maharashtra). Hikal’s R&T facilities are located at Pune. The Pharmaceutical manufacturing facilities are situated in Jigani (Bengaluru) and Panoli (Gujarat). Hikal is the first Indian life-sciences company to receive the Responsible Care® certification governed by the International Council of Chemical Associations (ICCA).

Safe Harbor Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further information, please contact

Company :

Hikal Limited

CIN: L24200MH1988PTC048028

Mr. Anish Swadi
anish_swadi@hikal.com

www.hikal.com

Investor Relations Advisors :

Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Ms. Payal Dave
payal.dave@sgapl.net
+91 9819916314

www.sgapl.net